DefiniGEN closes Series A
DefiniGEN, a provider of stem cell life science products and services, has closed a $3.83 million Series A funding round. The funding round was led by Cambridge Enterprise and 24 Haymarket, with existing investors Dr. Jonathan Milner, CEO, Abcam Plc, Providence Investment Company, and Cambridge Capital Group. New investors include LBA, Wren Capital and Ranworth Capital.
2 June 2014•2 mins read
